The review also discusses current issues with clinical trial access and generalisability of trial results. Provide hope to dementia patients Infrastructure required to administer drugs including ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Cerebral amyloid angiopathy (CAA) is a common but often asymptomatic disease, characterized by deposition of amyloid in cerebral blood vessels. We describe the successful treatment of CAA ...

they create amyloid deposits, which can damage organs and tissues. A doctor can diagnose amyloidosis with several tests. These include: lab tests, such as a urine analysis or blood test imaging ...

Cerebral spinal fluid examination revealed ... No neurofibrillary tangles or amyloid plaques were found in the parenchyma. Reactive gliosis, strong upregulation of microglia and multiple ...

Trial populations in this presymptomatic group could be enriched on the basis of biomarkers of axonal injury and neurodegeneration, including diffusion tensor imaging, blood neurofilament levels or ...

We propose a multimodal evaluation, including EEG surveillance, clinical assessment at discharge and cerebral imaging, to increase neonatal screening capacity for a more efficient follow-up. We ...

Background: Cerebral amyloid angiopathy (CAA), in which amyloid-β (Aβ) is deposited in cerebral and meningeal blood vessels, is associated with not only stroke but also cognitive dysfunction. CAA is ...

Background: Cerebral amyloid angiopathy (CAA) is a hemorrhagic cerebrovascular disease that is thought to be due to excess protein deposition in vessel walls that lead to fragility and increase the ...

Tracking these MPL-cells revealed that they sometimes became trapped within a blood vessel. Some cells exited the imaging field following a period of obstruction while others remained in cerebral ...